-
HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.
DiabetesPugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum CJ, Eisenbarth GS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. -
T cell epitopes and post-translationally modified epitopes in type 1 diabetes.
Current Diabetes ReportsMcGinty JW, Marré ML, Bajzik V, Piganelli JD, James EA -
β cell ER stress and the implications for immunogenicity in type 1 diabetes.
Frontiers in Cell and Developmental BiologyMarré ML, James EA, Piganelli JD -
Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis.
The Journal of Clinical InvestigationNagy N, Kaber G, Johnson PY, Gebe JA, Preisinger A, Falk BA, Sunkari VG, Gooden MD, Vernon RB, Bogdani M, Kuipers HF, Day AJ, Campbell DJ, Wight TN, Bollyky PL -
Hyaluronan: A Mediator of Islet Dysfunction and Destruction in Diabetes?
The Journal of Histochemistry and CytochemistryHull RL, Bogdani M, Nagy N, Johnson PY, Wight TN -
The detection of glycosaminoglycans in pancreatic islets and lymphoid tissues.
Methods in Molecular BiologyBogdani M, Simeonovic C, Nagy N, Johnson PY, Chan CK, Wight TN -
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development.
PLoS OneChow IT, Yang J, Gates TJ, James EA, Mai DT, Greenbaum CJ, Kwok WW -
Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes.
DiabetesMcGinty JW, Chow IT, Greenbaum CJ, Odegard JM, Kwok WW, James EA -
Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis.
DiabetesBogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, Wight TN -
Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr.
Pediatric DiabetesMax Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum CJ, Becker D, Petersen JS, Hansen L, Mortensen HB -
Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease.
Physiological ReportsAfkarian M, Hirsch IB, Tuttle KR, Greenbaum CJ, Himmelfarb J, de Boer IH -
Low HERV-K(C4) copy number is associated with type 1 diabetes.
DiabetesMason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT -
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Diabetes CareOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Anti-cytokine therapies in T1D: Concepts and strategies.
Clinical ImmunologyNepom GT, Ehlers M, Mandrup-Poulsen T -
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
DiabetesHerold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team.
